About Atlastin-3
Atlastin-3 (ATL3) is a protein
from Homo sapiens identified by UniProt accession
Q6DD88, 541 residues long.
MolForge cross-references it against 0 known binders and
34 disease associations.
Target properties
| Protein name | Atlastin-3 |
| UniProt accession | Q6DD88 |
| Gene | ATL3 |
| Organism | Homo sapiens |
| Length | 541 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (34)
Diseases linked to this target (Open Targets).
- neuropathy, hereditary sensory, type 1F · score 0.66
- hereditary sensory and autonomic neuropathy type 1 · score 0.58
- genetic disorder · score 0.19
- Charcot-Marie-Tooth disease · score 0.11
- prostate cancer · score 0.11
- Charcot-Marie-Tooth disease axonal type 2N · score 0.11
- Familial prostate cancer · score 0.11
- prostate carcinoma · score 0.11
- COVID-19 · score 0.02
- Flavivirus Infections · score 0.01
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q6DD88-F1 | alphafold | PREDICTED | 86.80 | — |
Amino-acid sequence (541 residues)
MLSPQRVAAA ASRGADDAME SSKPGPVQVV LVQKDQHSFE LDEKALASIL LQDHIRDLDV VVVSVAGAFR KGKSFILDFM LRYLYSQKES GHSNWLGDPE EPLTGFSWRG GSDPETTGIQ IWSEVFTVEK PGGKKVAVVL MDTQGAFDSQ STVKDCATIF ALSTMTSSVQ IYNLSQNIQE DDLQQLQLFT EYGRLAMDEI FQKPFQTLMF LVRDWSFPYE YSYGLQGGMA FLDKRLQVKE HQHEEIQNVR NHIHSCFSDV TCFLLPHPGL QVATSPDFDG KLKDIAGEFK EQLQALIPYV LNPSKLMEKE INGSKVTCRG LLEYFKAYIK IYQGEDLPHP KSMLQATAEA NNLAAAASAK DIYYNNMEEV CGGEKPYLSP DILEEKHCEF KQLALDHFKK TKKMGGKDFS FRYQQELEEE IKELYENFCK HNGSKNVFST FRTPAVLFTG IVALYIASGL TGFIGLEVVA QLFNCMVGLL LIALLTWGYI RYSGQYRELG GAIDFGAAYV LEQASSHIGN STQATVRDAV VGRPSMDKKA Q
Explore Atlastin-3 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets